Tarsus Pharmaceuticals
TARS
194 hedge funds and large institutions have $2.26B invested in Tarsus Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 67 increasing their positions, 72 reducing their positions, and 34 closing their positions.
122% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $627K
3% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 34
1% more capital invested
Capital invested by funds: $2.23B → $2.26B (+$29.2M)
0.33% more ownership
Funds ownership: 105.31% → 105.65% (+0.33%)
1% less funds holding
Funds holding: 195 → 194 (-1)
7% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 72
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$73.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$45.1M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$35.5M |
| 4 |
O
OrbiMed
New York
|
+$32.3M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$25.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$19.6M |
| 2 |
BlackRock
New York
|
-$19M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$16.9M |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$12.4M |
| 5 |
PA
Perceptive Advisors
New York
|
-$10.3M |
TARS Hedge Fund Activity: Q1 2025 in Review
194 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q1 2025, worth a combined $2.26B — up 1.3% from $2.23B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TARS positions and 34 closed out — a net gain of 1 holder — while 67 added to existing stakes and 72 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $73.4M. The largest seller was Millennium Management, cutting an estimated $19.6M.
- 194 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q1 2025, down from 195 in Q4 2024.
- Funds reported $2.26B of Tarsus Pharmaceuticals stock for Q1 2025, up 1.3% quarter-over-quarter.
- 35 funds opened new Tarsus Pharmaceuticals positions in Q1 2025 and 34 closed out, a net change of +1 holder.
- The largest Tarsus Pharmaceuticals buyer in Q1 2025 was Deep Track Capital, an estimated $73.4M added.
- The largest Tarsus Pharmaceuticals seller in Q1 2025 was Millennium Management, an estimated $19.6M sold.
Based on aggregated 13F filings for Q1 2025.